In conclusion, we showed that the individual outcome of anti PD-1 therapy in patients with NSCLC can be predicted by metabolomic analysis of serum collected before commencing treatment, with >80% accuracy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.